Secoisolariciresinol Diglucoside Exerts Anti-Inflammatory and Antiapoptotic Effects through Inhibiting the Akt/IκB/NF-κB Pathway on Human Umbilical Vein Endothelial Cells
SDG mediated reduced LPS-mediated cell injury and apoptosis. (a) LPS (0, 1, 10, 20, 30, and 40 μg/mL) was used to treat HUVECs for 12, 24, and 36 h. Cell viability was analyzed by CCK-8 assay. (b) Pretreated the cells with SDG (10 μM) for 24 h, followed by LPS for 24 h. SDG increased the survival rate of cells in LPS-induced HUVECs. (c) Representative immunoblots of cleaved caspase-3, Bcl-2, and Bax proteins in different groups. (d–f) Semiquantitative analysis of the relative levels of cleaved caspase-3, Bcl-2, and Bax by a densitometric analysis. Error bars represent .,, and represent ,, and , respectively. All experiments were performed in triplicate. LPS: lipopolysaccharide; SDG: secoisolariciresinol diglucoside.
Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.